Awakn Life Sciences recently announced results from its double-blind, placebo-controlled trial, which is exploring the effectiveness of ketamine-assisted therapy in treating alcohol use disorder. The results show promise, offering hope for millions of individuals around the globe who suffer from alcohol addiction.
The trial comprised of 96 patients suffering from severe alcohol use disorder who were randomly divided into four groups. The first group received three ketamine IV infusions and proprietary, manualized therapy. The second group received proprietary, manualized therapy and the placebo, which was three saline infusions. The third group received alcohol education and ketamine infusions, while the fourth group received alcohol education and the placebo.
Following treatment, the first group achieved complete abstinence in 162 of 180 days in the six-month period, which is a significant improvement of about 84%. The groups that received proprietary, manualized therapy also experienced considerable decreases in the risk of mortality, with findings showing that one in eight patients would have died in 12 months without the psychedelic treatment. This number dropped to one in ei80ghty for those who received the psychedelic treatment.
The findings show that patients with alcohol use disorder being administered with low doses of ketamine combined with manualized therapy were more likely to achieve alcohol abstinence and less likely to relapse by the six-month mark in comparison with control groups. The findings also show that participants who received ketamine-assisted therapy were 90% less likely to die the following year.
No serious adverse effects were reported from the trial, which was carried out by Celia Morgan, a psychopharmacology professor at the University of Exeter. The research also produced numerous encouraging secondary outcomes ranging from an increase in the ability of participants to experience pleasure plus a statistically substantial reduction in depression and improved liver function in the participants.
The positive results pave the way for a phase 3 trial as the company works toward gaining regulatory approval through the National Health Service for ketamine-assisted therapy as an alcohol use disorder treatment.
In a statement, Morgan stated that alcohol use disorder was a persistent and prevalent public health issue impacting roughly 390 million individuals around the globe. She explained that the rates of treatments for the disorder were low while relapse rates after treatment were high, which emphasized the need for new and more effective treatments.
The trial’s findings were reported in the “American Journal of Psychiatry.”
Such studies provide additional proof that companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) that operate multiple ketamine clinics are bringing this therapeutic substance closer to the people who need it the most.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.